Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Engineered PBMC and PBSC in Advanced Malignancies
NCT03240861Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2017
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NY-ESO-1 T-cell receptor-engineered peripheral blood stem cells and mipetresgene autoleucel in solid tumor (advanced stage) and sarcoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of dose limiting toxicity at 90 days. Started Jul 2017; status: terminated.
02
Drugs
NY-ESO-1 T-cell receptor-engineered peripheral blood stem cellsmipetresgene autoleucel
03
Conditions
solid tumor (advanced stage)sarcoma
Beyond the preview
Go deeper on NCT03240861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240861.